These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18289015)

  • 1. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models.
    Liu JQ; Bai XF
    Curr Mol Med; 2008 Feb; 8(1):68-75. PubMed ID: 18289015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword?
    Tarazona R; Casado JG; Soto R; DelaRosa O; Peralbo E; Rioja L; Peña J; Solana R
    Cancer Immunol Immunother; 2004 Oct; 53(10):911-24. PubMed ID: 15127235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
    Hamaï A; Benlalam H; Meslin F; Hasmim M; Carré T; Akalay I; Janji B; Berchem G; Noman MZ; Chouaib S
    Tissue Antigens; 2010 Jan; 75(1):1-8. PubMed ID: 20196816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
    Khong HT; Restifo NP
    Nat Immunol; 2002 Nov; 3(11):999-1005. PubMed ID: 12407407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.
    Liu K; Caldwell SA; Greeneltch KM; Yang D; Abrams SI
    J Immunol; 2006 Mar; 176(6):3374-82. PubMed ID: 16517705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ; Kast WM
    Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-mediated apoptosis of cancer-specific T lymphocytes--reversing the "kiss of death"?
    Trapani JA
    Cancer Cell; 2002 Sep; 2(3):169-71. PubMed ID: 12242147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection.
    Chen PW; Uno T; Ksander BR
    J Immunol; 2006 Jul; 177(1):162-8. PubMed ID: 16785511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
    Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
    Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How tumors escape immune destruction and what we can do about it.
    Gilboa E
    Cancer Immunol Immunother; 1999 Oct; 48(7):382-5. PubMed ID: 10501851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.
    Lawson KA; Sousa CM; Zhang X; Kim E; Akthar R; Caumanns JJ; Yao Y; Mikolajewicz N; Ross C; Brown KR; Zid AA; Fan ZP; Hui S; Krall JA; Simons DM; Slater CJ; De Jesus V; Tang L; Singh R; Goldford JE; Martin S; Huang Q; Francis EA; Habsid A; Climie R; Tieu D; Wei J; Li R; Tong AHY; Aregger M; Chan KS; Han H; Wang X; Mero P; Brumell JH; Finelli A; Ailles L; Bader G; Smolen GA; Kingsbury GA; Hart T; Kung C; Moffat J
    Nature; 2020 Oct; 586(7827):120-126. PubMed ID: 32968282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ.
    Heckman KL; Schenk EL; Radhakrishnan S; Pavelko KD; Hansen MJ; Pease LR
    Eur J Immunol; 2007 Jul; 37(7):1827-35. PubMed ID: 17549735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic growth factor signaling mediating tumor escape from cellular immunity.
    Concha-Benavente F; Ferris RL
    Curr Opin Immunol; 2017 Apr; 45():52-59. PubMed ID: 28208102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
    Sutoh Yoneyama M; Tobisawa Y; Hatakeyama S; Sato M; Tone K; Tatara Y; Kakizaki I; Funyu T; Fukuda M; Hoshi S; Ohyama C; Tsuboi S
    J Biochem; 2017 Jun; 161(6):479-492. PubMed ID: 28011817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytotoxic T lymphocytes in cancer and autoimmunity].
    Prado-García H; Avila-Moreno F; López-González JS
    Rev Invest Clin; 2004; 56(5):629-39. PubMed ID: 15776868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.